Literature DB >> 12130617

Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

Brian R Budenholzer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12130617      PMCID： PMC1123680     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

3.  Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.

Authors:  Ratnakar Patti; Kiranmai Gumired; Pallu Reddanna; Leslie N Sutton; Peter C Phillips; C Damodar Reddy
Journal:  Cancer Lett       Date:  2002-06-06       Impact factor: 8.679

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study.

Authors:  T M MacDonald; S V Morant; G C Robinson; M J Shield; M M McGilchrist; F E Murray; D G McDevitt
Journal:  BMJ       Date:  1997-11-22

Review 6.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

7.  Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

Authors:  Chris Waskewich; Rosalyn D Blumenthal; Honglan Li; Rhona Stein; David M Goldenberg; Jack Burton
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

9.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

10.  Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

Authors:  Hubert Blain; Christelle Boileau; Françoise Lapicque; Emmanuelle Nédélec; Damien Loeuille; Cécile Guillaume; Alain Gaucher; Claude Jeandel; Patrick Netter; Jean-Yves Jouzeau
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335
  10 in total
  2 in total

1.  R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro.

Authors:  James K Liu; Smruti K Patel; David L Gillespie; Kum Whang; William T Couldwell
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

Review 2.  Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis.

Authors:  Rebecca S Y Wong
Journal:  Adv Pharmacol Sci       Date:  2019-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.